Abstract: A device for holding and monitoring a predetermined dose of a product during a freezing, drying and/or lyophilization process, includes a mold having a receptacle part for containing the predetermined dose of the product in direct contact with the receptacle part, a sensor, contacting the mold or integrated in the mold, for measuring a physical characteristic and/or quantity, and a transmitter for transmitting the measured characteristic and/or quantity in the form of a sensor signal to a control unit for controlling a heating and/or cooling element, integrated in the device, for heating and/or cooling a predetermined dose of product during a freezing, drying and/or lyophilization process, in the lyophilization process. The device relates in further aspects to a system and a method.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Abstract: This invention relates to xanthohumol-based compositions, yielded in a hot-melt extrusion process (HME) using one or more water-soluble nutritionally and/or cosmetically acceptable thermoplastic polymers, such as selected from hydroxypropylmethyl-cellulose (HPMC), a vinylpyrrolidone-vinyl acetate copolymer, and combinations thereof. The present invention also relates to topical and oral formulations comprising such extruded xanthohumol-based compositions, as well as the use of one or more water-soluble nutritionally and/or cosmetically acceptable thermoplastic polymers in a hot-melt extrusion process of xanthohumol.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Abstract: A device for holding and monitoring a predetermined dose of a product during a freezing, drying and/or lyophilization process, includes a mold having a receptacle part for containing the predetermined dose of the product in direct contact with the receptacle part, a sensor, contacting the mold or integrated in the mold, for measuring a physical characteristic and/or quantity, and a transmitter for transmitting the measured characteristic and/or quantity in the form of a sensor signal to a control unit for controlling a heating and/or cooling element, integrated in the device, for heating and/or cooling a predetermined dose of product during a freezing, drying and/or lyophilization process, in the lyophilization process. The device relates in further aspects to a system and a method.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Abstract: This invention relates to xanthohumol-based compositions, yielded in a hot-melt extrusion process (HME) using one or more water-soluble nutritionally and/or cosmetically acceptable thermoplastic polymers, such as selected from hydroxypropylmethyl-cellulose (HPMC), a vinylpyrrolidone-vinyl acetate copolymer, and combinations thereof. The present invention also relates to topical and oral formulations comprising such extruded xanthohumol-based compositions, as well as the use of one or more water-soluble nutritionally and/or cosmetically acceptable thermoplastic polymers in a hot-melt extrusion process of xanthohumol.

Abstract: The present invention relates to solid pharmaceutical dosage forms suitable for use as drinking water medication. More in particular, the present invention provides solid pharmaceutical dosage forms comprising a pharmaceutically active agent, a non-ionic surfactant having an Hydrophilic Lipophilic Balance (HLB) of at least 8, and a maltodextrin. The present invention also provides the use of such pharmaceutical dosage forms in veterinary medicine, more in particular as drinking water medication; as well as methods for preparing such pharmaceutical dosage forms.

Abstract: The present invention in general relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one active ingredient and at least one dicarboxylic acid. It in particular relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one anthelmintic drug and at least one dicarboxylic acid. The invention further relates to uses, methods for use and methods for manufacturing the pharmaceutical suspension according to this invention.

Abstract: This disclosure relates to predicting the carcinogenicity of compounds. More in particular, this application discloses methods to detect whether a compound is a non-genotoxic carcinogen and methods to discriminate between genotoxic and non-genotoxic carcinogens based on in vivo stem cell proliferation patterns in flatworms.

Abstract: This disclosure relates to predicting the carcinogenicity of compounds. More in particular, this application discloses methods to detect whether a compound is a non-genotoxic carcinogen and methods to discriminate between genotoxic and non-genotoxic carcinogens based on in vivo stem cell proliferation patterns in flatworms.

Abstract: The present invention relates to solid pharmaceutical dosage forms suitable for use as drinking water medication. More in particular, the present invention provides solid pharmaceutical dosage forms comprising a pharmaceutically active agent, a non-ionic surfactant having an Hydrophilic Lipophilic Balance (HLB) of at least 8, and a maltodextrin. The present invention also provides the use of such pharmaceutical dosage forms in veterinary medicine, more in particular as drinking water medication; as well as methods for preparing such pharmaceutical dosage forms.

Abstract: This disclosure relates to predicting the carcinogenicity of compounds. More in particular, this application discloses methods to detect whether a compound is a non-genotoxic carcinogen and methods to discriminate between genotoxic and non-genotoxic carcinogens based on in vivo stem cell proliferation patterns in flatworms.

Abstract: A pharmaceutical composition for oral use including a release formulation formed by extrusion, said formulation in particular including a polyurethane polymer and an active agent. A process of manufacturing the formulation, uses and methods of treatment.

Abstract: The present invention in general relates to an intravaginal delivery system as well as uses thereof and methods for manufacturing and use of the same. In particular the present invention relates to an intravaginal delivery system for the controlled release of one or more organic acids, such as lactic acid; said intravaginal delivery system being characterized in that it comprises a combination of ethylene vinyl acetate (EVA) copolymers and carboxylic polymers, such as for example methacrylic acid-methacrylic ester copolymers.

Abstract: The present invention in general relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one active ingredient and at least one dicarboxylic acid. It in particular relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one anthelmintic drug and at least one dicarboxylic acid. The invention further relates to uses, methods for use and methods for manufacturing the pharmaceutical suspension according to this invention.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising a multi-layered release formulation formed by co-extrusion. Said formulation in particular comprises a core layer comprising at least one polymer selected from polycaprolactone, ethylcellulose, or combinations thereof; and a coat layer comprising at least one (co)polymer selected from the list comprising: polyethylene oxide; polyethylene glycol; Basic Butylated Methacrylate (co)polymer; a (co)polymer of polyvinylcaprolactam, PEG and polyvinylacetate; or combinations thereof.